BerGenBio ASA Secures NOK 100 Million Shareholder Loan Facility from Meteva as
hospitalized COVID-19 patients. The facility will be available for use until the earlier of an equity issue or March 31, 2024, and contains customary covenants and event of default provisions. BerGenBio may, subject to certain conditions, draw on the facility from Second Quarter 2023. The facility will not be amortizing and any drawn amounts are to be repaid or converted to equity on or before December 31, 2024.